Please login to the form below

Not currently logged in

Vyndaqel a bright spot as Pfizer comes under pressure

Faces a challenging period as big brands experience a slowdown


Pfizer’s restructuring into a leaner company is still ongoing, and in the meantime its facing a challenging period as big brands like Ibrance and Xeljanz show evidence of a slowdown.

The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing analysts sales expectations, and it recorded a net loss of $337m.

Ibrance was up 15% to $1.28bn in the quarter, while Xeljanz climbed 11% to $607m. The top line was however dragged down by the onset of generic competition in the US to severe pain drug Lyrica (pregabalin), which plunged to $433m from $1.32bn a year ago.

Meanwhile, vaccine blockbuster Prevnar also continued its slowdown, but still brought in $1.58bn in the quarter, and anticoagulant Eliquis (apixaban) continued its strong growth with a 21% gain to $1.1bn.

The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier following its FDA approval to treat ATTR cardiomyopathy last September.

As of the end of 2019 more than 9,000 ATTR cardiomyopathy patients had been diagnosed in the US – raising the diagnosis rate from 1% pre-Vyndaqel launch to around 9%, according to Pfizer. More than 5,500 patients had been prescribed the drug at that cut-off and over 3,000 had already received it.

The results come ahead of Pfizer’s plan to spin out its Upjohn generic drugs business into a joint venture with Mylan called Viatris, due to complete in the middle of this year, and after it partnered with GlaxoSmithKline (GSK) on a JV for its consumer health business.

Upjohn sales were weak in the quarter, down 16% largely because of the impact of the US patent expiry for Lyrica – the biggest-selling drug in its portfolio – and that followed a 25% decline in the prior quarter. Meanwhile, Pfizer revealed on the call that the JV may also take control of two additional subsidiary companies – autoinjector specialist Meridian and a Japanese generics unit.

Pfizer’s new chief executive Albert Bourla said on a conference call that the company is heading for accelerated growth once the restructuring efforts bed in, and that 2020 is a “transformational” year as it pivots to a small organisation focused on new, patent-protected medicines.

The aim is to free up cash to invest in R&D, and in the fourth quarter its spending in this area rose 15% to $2.8bn. The company’s pipeline includes 15 new drugs or indications that it thinks have the potential to generate $1bn or more in annual sales by 2022.

Key candidates coming through late-stage development include JAK1 inhibitor abrocitinib for atopic dermatitis, a vaccine for Clostridium difficile infections, and vaccine against Clostridium difficile and Eli Lilly-partnered tanezumab, which has the potential to be the first in a new class of non-opioid painkillers.

Article by
Phil Taylor

29th January 2020

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...